This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Prestige Consumer (PBH) Stock Rallies 20% in a Year: Here's Why
by Zacks Equity Research
Prestige Consumer (PBH) benefits from a robust healthcare brand portfolio and solid demand.
Here's Why Investors Should Invest in Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on strong growth in the Diagnostics business and upbeat guidance.
5 Dividend Aristocrats to Buy as Things Look Dicey for Wall Street
by Tirthankar Chakraborty
As stocks are subjected to bouts of volatility, place bets on dividend aristocrats like Caterpillar (CAT), Abbott Laboratories (ABT), McDonald's (MCD), Aflac (AFL) and Automatic Data Processing (ADP) for steady income.
Abbott (ABT) Closes Acquisition Deal of Bigfoot Biomedical
by Zacks Equity Research
Abbott's (ABT) footprint in the diabetes care market is increased by the Bigfoot Biomedical acquisition.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Abbott (ABT) Stock Moves -1.35%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $98.93 in the latest trading session, marking a -1.35% move from the prior day.
Abbott (ABT) to Commercialize Biosimilars in Emerging Markets
by Zacks Equity Research
Abbott (ABT) is set to commercialize several biosimilar molecules in key emerging markets via an expanded collaboration with mAbxience.
All You Need to Know About Abbott (ABT) Rating Upgrade to Buy
by Zacks Equity Research
Abbott (ABT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Abbott (ABT) Broadens Electrophysiology Footprint With TactiFlex
by Zacks Equity Research
The successful deployment of Abbott's (ABT) TactiFlex Ablation Catheter, Sensor Enabled in Canada broadens the company's global footprint in the electrophysiology space.
Abbott (ABT) Unveils Connected Diabetes App With New Pact
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre portfolio is the world's top sensor-based CGM system, changing the lives of over 5 million people.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $102.45 in the latest trading session, marking a +1.71% move from the prior day.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Abbott (ABT) to Advance Diabetes Care With New Acquisition
by Zacks Equity Research
Abbott's (ABT) recent deal will enable it to create more interconnected solutions to improve the personalization and accuracy of diabetes control.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $100.88 in the latest trading session, marking a -1.92% move from the prior day.
Abbott's (ABT) New Positive Data Favors OCT in Stent Implantation
by Zacks Equity Research
Abbott's (ABT) latest late-breaking data reflects OCT's potential to improve clinical practice related to stent placement.
The Zacks Analyst Blog Highlights Oracle, Abbott Laboratories, Sanofi, Realty Income and Hilton Worldwide Holdings
by Zacks Equity Research
Oracle, Abbott Laboratories, Sanofi, Realty Income and Hilton Worldwide Holdings are part of the Zacks top Analyst Blog.
Top Stock Reports for Oracle, Abbott & Sanofi
by Sheraz Mian
Today's Research Daily features new research reports on 15 major stocks, including Oracle Corporation (ORCL), Abbott Laboratories (ABT) and Sanofi (SNY).
Abbott's (ABT) Libre Gains Momentum Amid Low Testing Sales
by Zacks Equity Research
Banking on the successful execution of Abbott's (ABT) branded generic operating model, EPD is well positioned for sustained growth in many of the growing pharmaceutical markets.
Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Abbott (ABT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $104.41 in the latest trading session, marking a +0.52% move from the prior day.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott (ABT) Stock Moves -1.31%: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $103.75, marking a -1.31% move from the previous day.
Alcon (ALC) Q2 Earnings Surpass Estimates, Margins Increase
by Zacks Equity Research
Alcon (ALC) delivers better-than-expected earnings and revenues in the second quarter of 2023.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Boston Scientific's (BSX) POLARx System Gets FDA Approval
by Zacks Equity Research
Boston Scientific's (BSX) POLARx enables doctors to expand and modify the new POLARx catheter to match a patient's unique anatomy during an ablation treatment.